A research team led by the University of Cincinnati revealed that patients in need of kidney can opt for transplantation by safely receiving a kidney from an HCV-infected donor. This report was published online in Annals of Internal Medicine.
It has always been believed that the internal organs stay in the same location in our bodies. But breaking news arose where a young woman in Michigan told doctors that she felt as if a ball was rolling inside her body whenever she moved. Upon being diagnosed, it was found that it was, in fact, not a ball but her right kidney. This condition was termed as ‘Floating Kidney’.
The ability to quantify the extent of kidney damage and predict the life remaining in the kidney, using an image obtained at the time when a patient visits the hospital for a kidney biopsy, now is possible using a computer model based on artificial intelligence (AI).
It is estimated by The National Kidney Foundation that over 100,000 patients are on the waiting list for kidney donors. A further 3,000 names are added to the list every year. An average patient has to wait for 3.6 years for a viable transplant. The patients are treated with dialysis while they are waiting for a transplant and only one in three patients survive for more than five years without a transplant. All that could change as scientists have developed the world’s first artificial kidney.
Boehringer Ingelheim has reason to believe its diabetes medication Jardiance can help fend off cardiovascular death, kidney failure and hospitalization for heart failure. And now, it’s developing a model to help predict which patients are best suited for treatment with the therapy.
Adult peoples with complicated urinary tract infections (cUTI) like pyelonephritis– a type of kidney infection caused by specific bacteria- suffer from many inconvenient problems like painful urination. It may lead to serious life threatening conditions including permanent kidney damage.
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.